Novasyte is honored to announce that we ranked 1,692 overall and 125 in the healthcare category on the 2018 Inc. 5000 List of Fastest-Growing Private Companies in America. This marks the sixth consecutive year achieving this recognition, putting us on an exclusive short list of only six percent of companies acknowledged for maintaining this level of continued growth over the years, including Microsoft, Timberland, Vizio, Intuit, Chobani, Oracle and Zappos.com.
Pharmaceutical manufacturers today are facing increasing pressures from The Trump Administration to reduce the cost of drug prices.
Announced on Wednesday of this week, Novartis indicated they would not be raising prices on its products for the remainder of 2018.1 They are joining Pfizer, whose chief executive officer, Ian Read, announced on July 10 that the company would delay increasing the prices on dozens of drug products until 2019, following President Trump publicly spotlighting the firm the day prior.2
This follows the initial statement from The Trump Administration in May 2018 regarding a comprehensive blueprint strategy to lower drug prices.